SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as members of the community speculate on potential price recovery and future utility, while many users continue to share optimistic long-term sentiment regarding the project's growth. Discussions are largely fueled by traders looking for a breakout and long-term supporters expressing patience for the token to eventually gain broader market traction.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors react to its AI-focused roadmap and active cross-chain ecosystem expansion, with community sentiment split between those accumulating on price weakness and others expressing frustration over long-term volatility. Enthusiasts are highlighting NEAR Intents and deflationary tokenomics as key fundamental catalysts that differentiate the project from broader market laggards.

ElizaOS

ELIZAOS is experiencing intense community polarization, with a vocal segment alleging systematic market manipulation by insiders and creators, while others remain optimistic about its long-term potential as an AI-agent operating system. This conflict is fueling high trading volume and volatility, as participants debate the project's viability amidst ongoing allegations of fraudulent practices.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is seeing heightened community engagement as investors speculate on its role as a high-performance, EVM-compatible Layer 1 blockchain, with many discussing its potential to scale and compete with established chains. Supporters are actively focused on long-term accumulation and staking strategies, often debating how market volatility and token unlock schedules influence its price discovery phase.

Rheinmetall AG is a holding company, which engages in the provision of development and sale of components, systems, and services for the security and civil industries. It operates through the following segments: Vehicle Systems, Weapon and Ammunition, Electronic Solutions, Sensors and Actuators, Materials and Trade, and Others. The Vehicle Systems segment offers a diverse portfolio of vehicles, including combat, support, logistics, and special vehicles. The Weapon and Ammunition segment includes products and solutions for threat-appropriate, firepower as well as comprehensive protection. The Electronic Solutions segment is involved in the chain of effects in the system network, from sensors and the networking of platforms and soldiers to the automated connection of effectors, as well as solutions for protection in cyberspace. The Sensors and Actuators consists of a product portfolio with exhaust gas recirculation systems, throttle valves, control dampers, and exhaust flaps for electromotors, solenoid valves, actuators and valve train systems, oil, water, and vacuum pumps for passenger cars, commercial vehicles, and light and heavy-duty off-road applications, as well as industrial solutions. The Materials and Trade segment focuses on the development of system components for the basic motor. The company was founded by Heinrich Ehrhardt on April 13, 1889 and is headquartered in Duesseldorf, Germany.

Rheinmetall AG - ADR

Rheinmetall AG is currently trending as investors capitalize on massive growth catalysts within the European defense sector, including major contract wins for artillery, armored vehicles, and naval systems. The community is actively debating the stock's long-term potential fueled by expanded NATO spending targets, while simultaneously monitoring volatility driven by shifts in geopolitical strategy and institutional accumulation.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom Video Communications is attracting attention as it tests long-term technical resistance, with traders debating whether a breakout from its multi-year base is fueled by its strategic early-stage investment in Anthropic or legitimate software business improvements. While some investors view the stock as an undervalued AI proxy with a strong balance sheet, others remain skeptical, pointing to intense competition from Microsoft Teams and historical volatility as reasons for caution.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

The US Global Jets ETF (JETS) is trending as investors weigh strong record-breaking travel demand against headwinds from geopolitical instability in the Middle East and concerns over elevated fuel and labor costs. Community discussions are centered on whether the sector will see a rally driven by easing oil prices or if ongoing operational disruptions and macroeconomic uncertainty will suppress potential growth.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing intense community speculation and active buying volume, fueled by rumors of major exchange relistings, upcoming network upgrades, and hopes for significant token burns. Investors are closely monitoring price action for a potential breakout, with many in the community expressing long-term optimism about a project revival despite ongoing concerns regarding past volatility and supply dilution.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending as investors digest significant institutional shifts, including a recent Uber stake filing and continued share buybacks, while the company scales autonomous vehicle deployments alongside a robust pipeline of WePilot ADAS integration. Community discussion centers on WeRide's competitive positioning in international markets like the UAE and Singapore, contrasting its multi-platform scaling strategy against broader sector volatility.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing intense scrutiny as a blend of soft sales commentary and a viral CEO interview creates a challenging narrative for the stock, causing investors to weigh the company's real estate-backed stability against its slowing consumer demand. While some community members view the current pullback as a value-buying opportunity in a defensive compounder, others are actively betting on further downside, citing leadership concerns and a broader retail consumer slowdown.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the transaction, the chief operating officer owned 4,517...

Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 4,517 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the sale, the chief operating officer...

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Morgan Stanley upped their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an 'equal weight' rating in a report on Tuesday...

Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00

Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an 'overweight' rating in a research note on Tuesday...

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho

Mizuho increased their target price on Axsome Therapeutics from $228.00 to $310.00 and gave the company an 'outperform' rating in a report on Tuesday...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eighteen h...

<ul class="summary-bullets"><li>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder.</li><li>The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.</li><li>Deutsche Bank analyst David Hoang hiked his price target for Axsome, citing a positive outlook for Auvelity’s commercial launch and growth potential.</li></ul>Axsome Therapeutics Inc. (AXSM) reported a mixed first quarter on Monday, but analysts on Wall Street remain optimistic about the company’s prospects.According to TheFly, Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating. The new price target implies an upside potential of nearly 21% from current levels.<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics shares</a> were up more than 10% in Monday morning’s trade. AXSM was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Bullish?</h2>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder. The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.Auvelity is Axsome’s treatment for agitation associated with dementia due to Alzheimer’s disease. Auvelity received a “clean label” approval from the U.S. Food and Drug Administration (FDA) last week, meaning that Auvelity will not carry a warning for increased risk of death in elderly patients with dementia.According to analysts at TD Cowen, this differentiates Auvelity from the only other approved therapy for ADA, Rexulti.Deutsche Bank analyst David Hoang raised the firm’s price target on Axsome Therapeutics to $281 from $245 and maintained a ‘Buy’ rating. Hoang cited a positive outlook for Auvelity’s commercial launch and growth potential as the reason for the price target hike.H.C. Wainwright analysts raised the firm’s price target on Axsome Therapeutics to $270 from $250 and maintained a ‘Buy’ rating, citing the FDA approval of Auvelity.<h2 class="st-heading-2">What Is Auvelity?</h2>Auvelity is an oral therapy targeting NMDA and sigma-1 receptors, having been approved in the U.S. for major depressive disorder and, more recently, for agitation associated with Alzheimer’s-related dementia.The company stated that about 223,000 prescriptions were written in Q1 2026, up 35% year-on-year and in line with fourth-quarter (Q4) levels. Axsome stated that payer coverage reached roughly 86% overall, including 78% in commercial plans and full coverage in Medicare and Medicaid.Following its FDA approval last week for Alzheimer’s agitation, the drug is set for a commercial launch in June. The company has also completed an expansion of its sales force to around 630 representatives, targeting a wide range of prescribers to support growth in both depression and Alzheimer’s-related use.<h2 class="st-heading-2">Axsome’s Mixed Q1</h2>Axsome Therapeutics’ Q1 results came in mixed on Monday. The company reported a loss of $1.26 per share, while Wall Street expected a loss of $0.86 per share, according to Fiscal.ai data.Axsome’s revenue came in at $191.2 million, edging past Wall Street’s estimates of $190.7 million.According to Koyfin data, the average 12-month price target for AXSM is $235.85, implying an upside of nearly 4% from current levels. Of the 20 analysts covering the stock, 19 have a ‘Buy’ or a ‘Strong Buy’ rating, while one has a ‘Hold’ recommendation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user expects Auvelity sales to reach at least $1.2 billion by the end of this year.<stembedurl>https://stocktwits.com/Georgejj/message/652182986</stembedurl>Another user thinks that big pharmaceutical companies are more willing than ever to acquire Axsome Therapeutics.<stembedurl>https://stocktwits.com/CloudMatt/message/652181828</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> is up 24% year-to-date and 102% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 27% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fnma-stock-in-focus-mizuho-fannie-mae-best-business-one-could-hope-for/cZQMvMpReJX">Mizuho Believes Fannie Mae Is Among The Best Businesses One Could Hope For — But Not Everyone Agrees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism?

Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating, implying an upside potential of nearly 21% from current levels.

Equity

Axsome Therapeutics Q1 Earnings Call Highlights

Axsome Therapeutics (NASDAQ:AXSM) reported first-quarter 2026 results highlighting strong year-over-year revenue growth, a major new FDA approval for Auvelity, and continued advancement across its neuroscience pipeline. Management also detailed commercial investments to support an upcoming launch in...

Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High Following Analyst Upgrade

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High After Analyst Upgrade...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest AXSM News

AXSMAxsome Therapeutics Inc